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Introduction: The effects of nocturnal noninvasive positive pressure ventilation (NIPPV) in pa-
tients with stable chronic obstructive pulmonary disease (COPD) remain controversial.
Methods: The Cochrane Airways group Register of Trials, MEDLINE, EMBASE and CINAHL were
searched up to August 2012. Individual patient data from randomised controlled trials on NIPPV
outcomes were selected for two separate meta-analyses: the first with follow-up of 3 months
and the second with 12 months of follow-up. Additionally, subgroup analyses within the NIPPV
group comparing IPAP levels, compliance and levels of hypercapnia on change in PaCO2 after 3
months were performed.
Results: Seven trials (245 patients) were included. All studies were considered of moderate to
high quality. No significant difference was found between NIPPV and control groups after 3 or
12 months of follow-up when looking at PaCO2 and PaO2, 6-minute walking distance, health-
related quality-of-life, forced expiratory volume in 1 s, forced vital capacity, maximal inspira-
tory pressure and sleep efficiency. Significant differences in change in PaCO2 after 3 monthsedical Center Groningen, Department of Pulmonary Diseases/Home Mechanical Ventilation, Triade
e Netherlands. Tel.: þ31 (0) 50 3613200; fax: þ31 (0) 50 3613900.
.nl, fransienstruik@hotmail.com (F.M. Struik).
3 Elsevier Ltd. All rights reserved.
3.10.007
330 F.M. Struik et al.were found for patients ventilated with IPAP levels of at least 18 cm H2O, for patients who used
NIPPV for at least 5 h per night as well as for patients with baseline PaCO2 of at least 55 mm Hg
when compared to patients with lower IPAP levels, poorer compliance or lower levels of hyper-
capnia.
Discussion: At present, there is insufficient evidence to support the application of routine
NIPPV in patients with stable COPD. However, higher IPAP levels, better compliance and higher
baseline PaCO2 seem to improve PaCO2.
ª 2013 Elsevier Ltd. All rights reserved.Introduction
Chronic Obstructive Pulmonary Disease (COPD) is an
important cause of morbidity and mortality world-wide [1].
There is a wide range of therapeutic approaches to this
disease, but to date, only smoking cessation and the pro-
vision of long term oxygen therapy to hypoxemic patients
have been shown to prolong life [2]. Other treatment op-
tions which can be considered when pharmacological
therapy is optimal include pulmonary rehabilitation [3],
lung volume reduction surgery [4] and in extreme cases lung
transplantation [5]. Currently, several studies are ongoing
in the field of severe emphysema, looking at the possibil-
ities of bronchoscopic lung volume reduction [6].
In COPD patients with chronic hypercapnic respiratory
failure nocturnal noninvasive positive pressure ventilation
(NIPPV) might be beneficial. NIPPV is currently applied as
evidence based therapy in COPD patients admitted to
hospital with acute hypercapnic respiratory failure due to
an exacerbation. It has been shown that it reduces hospital
deaths and complications associated with treatment and
length of hospital stay [7]. However, studies and systematic
reviews on the effects of chronic NIPPV in stable hyper-
capnic COPD have been contradictory [8,9] due to small
number of patients, uncontrolled designs and different
levels of inspiratory pressures delivered by the ventilator.
Several theories exist as to why chronic NIPPV might be
beneficial. Firstly, NIPPV has been shown to improve sleep
time and efficiency [10]. Secondly, NIPPV during sleep may
ameliorate nocturnal hypoventilation and allows the res-
piratory centre to be reset and reduce daytime hypercapnia
[11]. Thirdly, NIPPV might rest the chronically fatigued
muscles, leading to recovery of the inspiratory muscle
function [12]. Lastly it has been suggested that NIPPV de-
creases hyperinflation leading to an improvement in respi-
ratory mechanics, such as an increase in forced expiratory
volume in 1 s (FEV1) and a decrease in residual volume (RV)
[11,13].
Over the last few years, several non randomised un-
controlled trials have reported on a new approach to NIPPV
aimed at maximally reducing arterial carbon dioxide pres-
sure (PaCO2) levels by means of high inspiratory positive
airway pressure (IPAP) and high backup rates [14]. These
studies, all with a mean IPAP of around 30 cm H2O have
shown improvements in blood gases during spontaneous
breathing as well as improvements in lung function and
health-related quality-of-life (HRQL). A randomised
controlled crossover trial [15] comparing 6 weeks of high-
intensity NIPPV (Hi-NIPPV) (mean IPAP 29 cm H2O incontrolled mode) to 6 weeks of low-intensity NIPPV (mean
IPAP 15 cm H2O in assist mode) found significant improve-
ments compared to baseline only in the Hi-NIPPV group in
arterial carbon dioxide tension (PaCO2), FEV1, forced vital
capacity (FVC) and HRQL. Interestingly, patients showed a
higher compliance in the high-intensity NPPV group.
To give an update of the current literature we per-
formed a meta-analysis based on individual patient data
from all included studies. First results of this analysis have
already been reported in the Cochrane Database of Sys-
tematic Reviews [16].
Our objectives were to:
1) Assess the between group effects among stable COPD
patients with and without NIPPV on blood gasses, 6-
minute walking distance (6MWD), health-related qual-
ity-of-life, lung function, respiratory muscle function,
sleep efficiency (SE) and dyspnoea.
2) Perform sub analyses within the NIPPV group to explore
the effects of IPAP levels, compliance, as well as level
of hypercapnia on PaCO2.Methods
Search strategy
A search was done up to August 2012 in all records in the
Airways register of the Cochrane Institute coded as ‘COPD’
using the following search string:/(nasal OR mechanical OR
noninvasive OR non-invasive or “noninvasive” or positive OR
intermittent OR bi-level OR “bi level” OR airway* OR
controlled OR pressure OR support AND (ventilat*)) OR
(NIPPV)/. This contains records downloaded from MEDLINE,
EMBASE and CINAHL, as well as records identified through
hand searching and abstracts from meetings of the Amer-
ican Thoracic Society, British Thoracic Society and Euro-
pean Respiratory Society. In addition, we searched the
bibliographies of each RCT for additional papers that may
contain RCTs.
Selection criteria
We included randomised controlled trials in stable patients
with COPD, comparing non-invasive positive pressure
ventilation (NIPPV) plus standard therapy with standard
therapy alone. The intervention in the treatment group
was NIPPV applied through nasal or face mask, for at least
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weeks. Participants also received their usual standard
COPD therapy which could comprise supplemental oxygen,
bronchodilators, theophylline and inhaled and/or oral
steroids.Data extraction and quality assessment
Two investigators (PJW and FMS) independently assessed all
titles and abstracts to identify and select potentially rele-
vant articles. When abstracts were selected, full papers
were retrieved and read in detail by both reviewers. After
identification of studies, authors were contacted for
permission to share anonymised individual patient data.
Supplied data were first checked against study publications
after which raw data from all included studies was copied
to one main database.
The quality of the eligible studies was assessed by
criteria for assessment of risk of bias provided in the
Cochrane Handbook for Systematic Reviews of In-
terventions [17]. The risk of bias of each study was assessed
by addressing the following domains: sequence generation,
allocation concealment, blinding of participants, personnel
and outcome measures, incomplete outcome data, selec-
tive outcome reporting, other sources of bias.Outcome measures
Primary outcome measures were arterial blood gas tensions
(PaCO2, PaO2), 6-minute walking distance (6MWD) and
health status (health-related quality-of-life measure-
ments). Secondary outcomes were lung function (forced
expiratory volume in 1 s (FEV1) and forced vital capacity
(FVC)), respiratory muscle function (muscle strength,
including maximal inspiratory pressure (PImax)), sleep ef-
ficiency (time asleep as percentage of total time in bed
(SE)) and dyspnoea.Figure 1 CONSORT flow diagram.Data synthesis and statistical analysis
The principal investigators of the trials included in the
meta-analysis kindly provided the individual data for each
of their study subjects. We therefore conducted an indi-
vidual data meta-analysis. In the case of crossover trials,
we considered only the first study period (prior to the
crossover). For each individual and for each outcome, we
calculated an absolute difference in score that defined
treatment effect. An overall treatment effect (and associ-
ated 95% confidence interval) was obtained from the dif-
ference in scores under each study condition (NIPPV minus
controls). A linear mixed model was used to compare the
treatment effects. Treatment and time of follow-up (3 and
12 months) were analysed with interaction terms as fixed
factors.
To consider the homogeneity among trials, a random
factor was defined in the statistical models. Statistical
significance (p < 0.05) in the test of homogeneity suggested
that the observed difference in the treatment effects was
in part attributable to the study effect.Subgroup analysis
Subgroup analyses were considered if sufficient studies and
a large enough sample size were to be included in the
analysis and if significant heterogeneity was found among
the outcomes of the trials. We identified a priori potential
sources of heterogeneity among the primary and secondary
outcomes:
1) The higher the level of IPAP, the higher the improve-
ment in PaCO2
2) The better the compliance of NIPPV, the greater the
improvement in PaCO2
3) The higher the level of hypercapnia at baseline, the
higher the improvement PaCO2
Differences between subgroups were analysed by using
an independent samples t-test when variables were nor-
mally distributed.
The division in levels of IPAP was based on results from
the study by Meecham Jones et al., [10] the only included
study presenting significant effects of NIPPV when looking
at daytime PaCO2. As the median IPAP setting in this study
was 18 cm H2O, subjects were divided into 2 groups with
levels of <18 cm H2O or 18 cm H2O.
For exploration of the effects of compliance with NIPPV
(hours of ventilation per night) on PaCO2, the NIPPV group
was divided into 2 groups based on less than or equal to at
least 5 h of ventilation per night. This was based on our
332 F.M. Struik et al.inclusion criteria that studies needed to have the intention
to ventilate patients for at least 5 h per night. Compliance
was measured in all studies by built-in time counters on the
NIPPV devices.
The division in PaCO2 at baseline into 2 groups of
<55 mm Hg and 55 mm Hg was made based on guidelines
from a consensus conference report [18].Results
Study selection and characteristics
The process for selection of reviews and trials for this re-
view is shown in Fig. 1. Seven papers met all inclusion
criteria and were included in the meta-analysis [10,19e24].
Five studies were excluded for following reasons: duration
of NIPPV too short (NIV protocol less than 4 h per night andTable 1 Characteristics of included studies.
Trial Study design
(compared to
treatment)
IPAP/
EPAP
Stud
Short term
Casanova (2000) [19] Parallel group
(LTOT)
12/4 52 r
36 c
51 m
Clini (2002) [20] Parallel-group
(LTOT)
14.4/3.8 90 r
78 c
56 m
Gay (1996) [21] Parallel-group
(sham)
10/2 13 r
10 c
52 m
Meecham Jones
(1995) [10]
Cross-over
(LTOT)
18/2 18 r
14 c
56 m
Sin (2007) [23] Parallel-group
(sham)
20/4 23 r
17 c
43 m
Strumpf (1991) [24] Cross-over
(standard care)
15/2 19 r
7 co
46 m
Long term
Clini (2002) [20] Parallel-group
(LTOT)
14.6/3.9 90 r
57 c
56 m
McEvoy (2009) [22] Parallel-group
(LTOT)
12.8/5.1 144
81 c
54 m
EPAP, expiratory positive airway pressure; FEV1, forced expiratory vo
variability; IPAP, inspiratory positive airway pressure ; LTOT, long term
PaCO2, arterial carbon dioxide tension while breathing room air; PI
pressure; 6MWD, 6-minute walking distance.at daytime) [25,26]; training of NIPPV too short (less than
three weeks [27] and two studies were not randomised
[28,29].
Of the seven studies included (Table 1), five had a length
of follow-up of at least 3 months [10,19,21,23,24], here
classified as short term group, and two had measurements
of at least 12 months of NIPPV, classified as long term group
[20,22].
Five studies applied NIPPV through a nasal mask
[10,19e21,24] and two by either a nasal or full face mask
[22,23]. Patients were recruited from Pulmonary Clinics
and admitted in five studies [10,19e22] as in-patients for
several days for training with NIPPV. In the two remaining
studies, patients were observed for several hours of
training (2e4) before going home with NIPPV the same day
[23,24].
Individual patient data was gathered from all studies
with in total 245 patients (Table 2).y population Outcomes
andomised patients,
ompleters. PaCO2
mHg, FEV1 0.84 L
Blood gasses, lung function,
PImax/PEmax, dyspnoea
after 3 months. Exacerbation
rate, hospital admissions,
intubations and mortality
after 12 months
andomised patients,
ompleters. PaCO2
m Hg, FEV1 0.75 L
Blood gasses and hospitalisations
after 3 months
andomised patients,
ompleters. PaCO2
m Hg, FEV1 0.68 L
Blood gasses, 6MWD, lung
function, PImax/PEmax and
sleep study
andomised patients,
ompleters. PaCO2
m Hg, FEV1 0.84 L
Blood gasses, 6MWD, HRQL,
lung function and sleep study
andomised patients,
ompleters. PaCO2
m Hg, FEV1 0.88 L
Blood gasses, 6 MWD, lung
function, HRV þ natriuretic
peptide measurements
andomised patients,
mpleters. PaCO2
m Hg, FEV1 0.54 L
Blood gasses, walking test,
lung function, PImax/PEmax,
sleep study, dyspnoea
andomised patients,
ompleters. PaCO2
m Hg, FEV1 0.75 L
Blood gasses, 6MWD, HRQL,
lung function, PImax, sleep
study, dyspnoea, hospitalisations,
mortality
randomised patients,
ompleters. PaCO2
m Hg, FEV1 0.65 L
Blood gasses, HRQL, lung
function, sleep study (only in
NIPPV group), hospitalisation
rates, survival
lume in 1 s; HRQL, health-related quality-of-life; HRV, heart rate
oxygen therapy; NIPPV, noninvasive positive pressure ventilation;
max, maximal inspiratory pressure; PEmax, maximal expiratory
Table 2 Demographic profile based on individual patient
data.
Control n Z 127 NIPPV n Z 118
Age (yrs) 68.4 (6.5) 64.6 (7.1)
Male n (%) 75 80
PaCO2 (kPa) 52.4 (6.8) 53.9 (8.3)
PaO2 (kPa) 54.6 (8.3) 55.7 (13.1)
FEV1 (L) 0.72 (0.23) 0.76 (0.31)
FVC (L) 2.01 (0.67) 2.02 (0.66)
IPAP (cm H2O) e 14.2 (3.1)
EPAP (cm H2O) 4.0 (1.0)
Compliance
(hours/day)
e 6.7 (2.2)
Data presented as mean  SD unless otherwise stated.
NIPPV; noninvasive positive pressure ventilation; PaCO2, arte-
rial carbon dioxide tension while breathing room air; PaO2,
arterial oxygen tension while breathing room air; FEV1, forced
expiratory volume in one second, post-bronchodilator; FVC,
forced vital capacity, post-bronchodilator; IPAP, inspiratory
positive airway pressure; EPAP, expiratory positive airway
pressure. Compliance in all studies was measured by built-in
time counters on the NIPPV devices.
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Overall all studies were considered of moderate to high
quality. All 7 studies described how randomisation was
performed and described adequate allocation conceal-
ment. Blinding of participants is difficult given the nature
of the intervention, but two studies managed to use a sham
device [21,23]. Blinding for physiological measurements
was done in 3 studies [19,20,24] but we judged outcomeTable 3 Individual patient data meta-analysis per outcome.
Outcomes Reference no. of
contributing trials
No. of (NIPPV/
control)
Short term (3 months)
PaO2, mm Hg [10,19e21,23,24] 79/83
PaCO2, mm Hg [10,19e21,23,24] 79/83
6MWD, m [10,21,23] 21/19
FEV1, L [10,19,21,23,24] 42/41
FVC, L [10,19,21,23,24] 42/40
PImax, cm H2O [19,21,24] 24/24
PEmax, cm H2O [19,21,24] 24/24
Sleep Efficiency % [10,21,24] 13/11
Long term (12 months)
PaO2, mm Hg [20,22] 62/56
PaCO2, mm Hg [20,22] 62/56
SGRQ, score [20,22] 50/53
FEV1, L [20,22] 63/62
FVC, L [20,22] 63/62
PaO2: arterial oxygen pressure; PaCO2: arterial carbon dioxide pressure
forced vital capacity, post-bronchodilator; PImax: maximal inspiratory
walking distance; SGRQ: St. George Respiratory Questionnaire; NIPPV:
interval.measurement was not likely to be influenced by lack of
blinding for personnel. All studies had drop-outs in both
groups due to intercurrent illnesses but with a slightly
higher percentage in the NIPPV groups also due to intoler-
ance to NIPPV. Two studies [21,24] were therefore classified
as high risk of attrition bias due to high dropout rates
(incomplete data Risk of bias for selective reporting was
unclear for all studies, but no other potential sources of
bias were found).
Meta-analyses
Table 3 shows the results of the meta-analysis using indi-
vidual patient data per outcome measurement. No signifi-
cant differences were found between NIPPV and control
groups after 3 or 12 months of follow-up. Treatment effects
for blood gasses and 6MWD after 3 months were modest
(2.5 mm Hg for PaCO2, 27.7 m for 6MWD) but confidence
intervals exceeded zero. PI and PEmax after 3 months
showed small treatment effects. Small negative effects
were calculated for PaO2 and HRQL after 12 months, FEV1
after both 3 and 12 months and for sleep efficiency after 3
months.
Heterogeneity was found for 3 outcome measures:
HRQL, PEmax and sleep efficiency, probably due to small
number of studies and therefore participants. For this
reason subgroup analysis for these outcomes was not
considered appropriate.
Subgroup analysis
Subgroup analyses within the NIPPV group (n Z 78)
comparing levels of IPAP, different number of hours of
ventilation and different levels of baseline hypercapnia onTreatment
effect
95% CI Homogeneity of
treatment effect,
p Value
1.30 0.71; 3.30 0.4787
2.50 5.28; 0.29 0.2607
27.7 11.0; 66.3 0.5662
0.01 0.09; 0.07 0.2413
0.00 0.13; 0.14 0.9570
4.87 1.48; 11.21 0.5538
22.09 23.53; 67.70 0.0002
9.11 38.09; 19.86 0.0022
1.77 8.60; 5.07 0.2412
0.96 3.55; 1.64 0.8290
0.90 19.21; 21.01 0.0288
0.01 0.07; 0.04 0.7445
0.04 0.12; 0.20 0.4510
; FEV1: forced expiratory volume in 1 s, post-bronchodilator; FVC:
pressure; PEmax: maximal expiratory pressure; 6MWD: six minute
noninvasive positive pressure ventilation; 95% CI: 95% confidence
Figure 2 Change in PaCO2 after 3 months of noninvasive
positive pressure ventilation (NIPPV). Change in PaCO2 after 3
months of NIPPV (PaCO2 baseline e PaCO2 after 3 months) for
A) high and low inspiratory positive airway pressure (<18 and
18 IPAP), B) high and low compliance (<5 and 5 ventilation
hours per night) and C) high and low baseline PaCO2 (<55 and
55 mm Hg). Figures display mean change scores and 95%
confidence intervals. Significant difference: *: p < 0.05,
**p < 0.01.
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Significant differences were found between patients
ventilated with IPAP levels of 18 cm H2O and higher and
patients ventilated with levels of below 18 cm H2O (PaCO2
change MD 3.24, 95% CI 5.83 to 0.64). Also, a signifi-
cant difference in change in PaCO2 after 3 months of NIPPV
was found between patients who used NIPPV for at least
5 h per night and those who used it for less than 5 h per
night (PaCO2 change MD 4.16, 95% CI 7.06 to 1.26).
Lastly, we found a significant difference between patients
with baseline PaCO2 of less than or equal to 55 mm Hg
(PaCO2 change MD4.02, 95% CI 6.25 to 1.79).Discussion
This systematic review on nocturnal NIPPV in stable COPD
included 7 studies and provided meta-analyses on the ef-
fects of NIPPV after 3 months and after 12 months of follow
up. Based on individual patient data of in total 245 patients
with stable hypercapnic COPD we did not find statistically
significant between group differences after 3 months of
NIPPV for gas exchange, exercise tolerance, lung function,
respiratory muscle strength and sleep efficiency. Meta-
analysis of long term data of 2 studies, did not show sig-
nificant improvement in gas exchange, HRQL or lung func-
tion after NIPPV when compared to standard treatment
[16].
Individual patient data permitted subgroup analysis
within the NIPPV group, and we found that improvements in
PaCO2 after 3 months were statistically greater in patients
who received IPAP levels of 18 cm H2O and higher.
Furthermore, when exploring the effects of compliance of
NIPPV on change in PaCO2 after 3 months, we found a sig-
nificant drop in PaCO2 in patients who used ventilation on
average for more than 5 h per night compared to those who
used it for less than 5 h per night. Additionally, patients
with baseline hypercapnia levels of over 55 mm Hg, showed
a significantly bigger improvement in PaCO2 after 3 months
than those who started NIPPV with PaCO2 levels below
55 mm Hg.
Although meta-analysis did not show any significant
differences on any of the outcome measures, the treatment
effect in PaCO2 improvement of 2.5 mm Hg after 3 months
of NIPPV could be of clinical importance. The confidence
intervals only just exceeded zero. The small sample size
precludes a definitive statement regarding the clinical im-
plications of NIPPV, other than stating that at present there
is insufficient evidence to support its widespread use.
When interpreting the results for the 6MWD, the high
upper limit of the confidence interval could be promising.
With an upper limit of 66 m, NIPPV probably has a beneficial
effect on walking distance at least in a subgroup of pa-
tients. Along these lines, a long term study comparing the
effects of NIPPV plus pulmonary rehabilitation [13] versus
rehabilitation alone showed significant differences in 6MWD
after 24 months in the NIPPV þ rehabilitation group but not
in the rehabilitation group alone.
The levels of IPAP used in the included studies were on
the low side (8e24 cm H2O). Although the median level of
IPAP in the short term group was only 14 cm H2O, given the
current debate on level of IPAP pressures we chose not to
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Based on results from the study by Meecham Jones [10] an
IPAP cut-off point of 18 cm H2O was chosen. In line with
those results, we found significant differences between
groups ventilated with IPAP levels of less than or equal to at
least 18 cm H2O. This raises the question as to whether Hi-
NIPPV pressures of around 30 cm H2O are required to
improve gas exchange during the day. The study by Dui-
verman et al. [13] comparing the effects of NIPPV in addi-
tion to rehabilitation showed a significant decrease in
PaCO2 after 3 and 24 months in the NIPPV þ rehabilitation
group as compared to the rehabilitation group. Although
mean levels of IPAP after 3 months were 20 cm H2O and
after 2 years 23 cm H2O, they found no relationship be-
tween the level of IPAP and change in PaCO2.
However, two recently published trials do advocate the
more aggressive forms of NIPPV using higher IPAP levels.
Dreher et al. [15]showed that the considerably higher
amount of air leakage which accompanies high-intensity
NIPPV does not reduce sleep quality when compared to
low-intensity NIPPV [30]. In addition, this form was even
better tolerated and they show that high-intensity NIPPV
with a mean of 29 mm H2O and high backup rate was su-
perior in controlling nocturnal hypoventilation. The study
by Murphy et al. [31] however challenges the need for the
accompanying high backup rates alongside high IPAP levels
in the high-intensity NIPPV form. They compared high-
intensity NIPPV with high-pressure NIPPV (high pressure
and low backup rate) and found no differences in mean
nocturnal ventilator usage, gas exchange or sleep quality.
However, high-intensity NPPV has raised some concerns
when focusing on cardiac output [32],as shown in a recent
randomised cross-over study [33] assessing the acute
physiological effects of low-intensity (Li-) NPPV and Hi-
NPPV in 15 patients with stable COPD. While both forms
significantly improved gas exchange compared to sponta-
neous breathing, Hi-NPPV induced a marked lowering in
cardiac output [34].
Even though this is speculative, this finding might
however not necessarily be negative as a reduction in
cardiac output may simply reflect that the heart is more
“rested” because of reduced oxygen consumption that
results from rested respiratory muscles. Nevertheless
cardiac function should be focused on in future trials with
Hi-NPPV in COPD.
Our finding of significant differences in PaCO2 after 3
months between patients with ‘low’ and ‘higher’ compli-
ance of NPPV was similar to results from the study by Dui-
verman et al. [35] who found that change in PaCO2 after 3
months correlated with the number of hours of NIPPV use
per day. This supports our inclusion criteria that only
studies with the intention to ventilate patients for at least
5 h per night were to be included in this meta-analysis.
Because of our access to individual patient data, we
noticed a subgroup that however was not able to achieve
5 h of ventilation per night making this comparison
possible. Remarkably, PaCO2 deteriorated after 3 months of
NIPPV for those patients with compliance of less than 5 h,
whilst it improved in the group of patients who used NIPPV
for more than 5 h per night. As the subgroup analyses were
performed within the NIPPV group with 78 patients in total,
these outcomes should be classified as hypothesis-generating and need further in-depth investigation in new
larger studies. An additional subgroup analysis could be
based on body mass index (BMI) (with assumed additional
sleep-related breathing disorders). Unfortunately we did
not have access to these data to explore the possible
benefit provided by NIPPV.
We were unable to comment on the symptom of dysp-
noea as different scales were used to assess it, including
the Borg scale, the Baseline and Transitional Dyspnea Index
and the MRC scale [19,20,24] and the length of follow up
varied among the studies.
Similar limitations were noted for HRQL, but we were
able to combine HRQL data from the 2 long-term studies
[20,22] who used the St. George Respiratory Questionnaire.
The absence of significant differences may reflect the St.
George questionnaire not being applicable for patients with
severe COPD and respiratory failure. The Maugeri Respira-
tory Failure questionnaire-28 (MRF-28) [36] and the Severe
Respiratory Insufficiency questionnaire (SRI) [37] were each
designed for patients with respiratory failure. Both have
been found to be reliable and valid in this population
[38,39].
Our study has several limitations. The quality of studies
was inconsistent: The 5 short term RCT’s [10,19,21,23,24]
included only small numbers of patients making it difficult
to assess the real benefit of NIPPV in stable COPD. For long
term outcomes only 2 RCT’s met all inclusion criteria
[20,22]. We performed meta-analysis only with patients
who completed the study. In 2 of the short term studies
[21,24], patients dropped out due to intolerance of NIPPV,
possibly introducing selection bias when only reporting
the completers. The 2 long term RCT’s [20,22], looking at
effects of NIPPV after 12 months also reported drop outs,
but a crucial difference compared to the short term
studies were the reasons for dropping out: this was mainly
due to progression of the disease and reluctance to return
to hospital for repeated measurements. These studies
highlight the difficulties researchers encounter when
including patients who are often in the end stage of their
disease.
Another study limitation is the absence of data on
exacerbation rate, hospital admissions or survival. Although
two both long-term studies [20,22] and 1 short term study
[19] did report some of these outcomes, the information
was insufficient to draw conclusions. Future studies that
include the above outcomes over an extended period will
enable conclusions to be made regarding the cost-
effectiveness of this treatment regimen.
In conclusion, this meta-analysis found no significant
effect of NIPPV after 3 or 12 months on gas exchange, ex-
ercise tolerance, quality of life, lung function, respiratory
muscle strength or sleep efficiency in stable COPD. As in-
dividual patient data was collected, this meta-analysis
enabled hypothesis generating subgroup analyses showing
that higher IPAP levels, more ventilation hours and higher
baseline PaCO2 seem to improve PaCO2 after 3 months of
NIPPV. Nevertheless there is currently insufficient evidence
to support the broader application of NIPPV in patients with
stable COPD. Despite the lack of positive results in this
meta-analysis further studies should focus on HI-NPPV as
these did show positive outcomes however, mainly ach-
ieved in uncontrolled studies.
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